Assignee
BLUEPRINT MEDICINES CORP
US·59 granted patents·47 pending applications·593 citations·filing 2014–2025
Top patents by PatentIndex Score
106 records- 0198US10030005B2Inhibitors of RETBLUEPRINT MEDICINES CORP·Filed 2016·Granted Jul 24, 2018·38 cites·30 claims
- 0298US9695165B2Inhibitors of the fibroblast growth factor receptorBLUEPRINT MEDICINES CORP·Filed 2015·Granted Jul 4, 2017·40 cites·20 claims
- 0398US9688680B2Compositions useful for treating disorders related to kitBLUEPRINT MEDICINES CORP·Filed 2015·Granted Jun 27, 2017·40 cites·21 claims
- 0497US11279688B2Inhibitors of RETBLUEPRINT MEDICINES CORP·Filed 2020·Granted Mar 22, 2022·5 cites·2 claims
- 0597US10000490B2Inhibitors of the fibroblast growth factor receptorBLUEPRINT MEDICINES CORP·Filed 2017·Granted Jun 19, 2018·30 cites·12 claims
- 0697US10000496B2Compositions useful for treating disorders related to kit and PDGFRBLUEPRINT MEDICINES CORP·Filed 2016·Granted Jun 19, 2018·32 cites·54 claims
- 0797US9994575B2Compositions useful for treating disorders related to kitBLUEPRINT MEDICINES CORP·Filed 2015·Granted Jun 12, 2018·32 cites·20 claims
- 0897US9944651B2Compositions useful for treating disorders related to kitBLUEPRINT MEDICINES CORP·Filed 2017·Granted Apr 17, 2018·33 cites·24 claims
- 0997US9884861B2Compositions useful for treating disorders related to kitBLUEPRINT MEDICINES CORP·Filed 2016·Granted Feb 6, 2018·32 cites·7 claims
- 1097US9340514B2Inhibitors of the fibroblast growth factor receptorBLUEPRINT MEDICINES CORP·Filed 2015·Granted May 17, 2016·43 cites·11 claims
- 1196US11827642B2Compositions useful for treating disorders related to KITBLUEPRINT MEDICINES CORP·Filed 2022·Granted Nov 28, 2023·2 cites·6 claims
- 1296US10807985B2Compositions useful for treating disorders related to kitBLUEPRINT MEDICINES CORP·Filed 2018·Granted Oct 20, 2020·7 cites·1 claims
- 1396US10227329B2Compounds useful for treating disorders related to RETBLUEPRINT MEDICINES CORP·Filed 2017·Granted Mar 12, 2019·19 cites·21 claims
- 1496US10196436B2Inhibitors of the fibroblast growth factor receptorBLUEPRINT MEDICINES CORP·Filed 2018·Granted Feb 5, 2019·17 cites·1 claims
- 1596US9994552B2Compositions useful for treating disorders related to kitBLUEPRINT MEDICINES CORP·Filed 2016·Granted Jun 12, 2018·31 cites·10 claims
- 1695US10584114B2Inhibitors of RETBLUEPRINT MEDICINES CORP·Filed 2018·Granted Mar 10, 2020·13 cites·3 claims
- 1795US10183928B2Inhibitors of RETBLUEPRINT MEDICINES CORP·Filed 2017·Granted Jan 22, 2019·13 cites·47 claims
- 1895US10035789B2Compounds useful for treating disorders related to RETBLUEPRINT MEDICINES CORP·Filed 2017·Granted Jul 31, 2018·31 cites·21 claims
- 1995US10017512B2Compounds and compositions useful for treating disorders related to NTRKBLUEPRINT MEDICINES CORP·Filed 2016·Granted Jul 10, 2018·29 cites·26 claims
- 2094US11534441B2MAP4K1 inhibitorsBLUEPRINT MEDICINES CORP·Filed 2021·Granted Dec 27, 2022·3 cites·25 claims
- 2194US10829493B2Compositions and methods for treating KIT- and PDGFRA-mediated diseasesBLUEPRINT MEDICINES CORP·Filed 2020·Granted Nov 10, 2020·5 cites·41 claims
- 2294US10378063B2RAF1 fusionsBLUEPRINT MEDICINES CORP·Filed 2015·Granted Aug 13, 2019·8 cites·6 claims
- 2394US10202365B22-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitorsBLUEPRINT MEDICINES CORP·Filed 2016·Granted Feb 12, 2019·20 cites·15 claims
- 2493US11718602B2EGFR inhibitorsBLUEPRINT MEDICINES CORP·Filed 2022·Granted Aug 8, 2023·2 cites·8 claims
- 2593US10233186B2Inhibitors of activin receptor-like kinaseBLUEPRINT MEDICINES CORP·Filed 2017·Granted Mar 19, 2019·16 cites·56 claims
- 2693US10221154B2Inhibitors of the fibroblast growth factor receptorBLUEPRINT MEDICINES CORP·Filed 2016·Granted Mar 5, 2019·11 cites·10 claims
- 2792US11273160B2RET inhibitor for use in treating cancer having a RET alterationBLUEPRINT MEDICINES CORP·Filed 2020·Granted Mar 15, 2022·5 cites·14 claims
- 2892US10774070B22-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitorsBLUEPRINT MEDICINES CORP·Filed 2018·Granted Sep 15, 2020·6 cites·14 claims
- 2991US11999744B2Crystalline forms of (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of makingBLUEPRINT MEDICINES CORP·Filed 2023·Granted Jun 4, 2024·2 cites·14 claims
- 3091US11970498B2CDK2 inhibitorsBLUEPRINT MEDICINES CORP·Filed 2023·Granted Apr 30, 2024·1 cites·26 claims
- 3190US12042495B2MAP4K1 inhibitorsBLUEPRINT MEDICINES CORP·Filed 2022·Granted Jul 23, 2024·1 cites·18 claims
- 3290US11046697B2Compounds and compositions useful for treating disorders related to NTRKBLUEPRINT MEDICINES CORP·Filed 2018·Granted Jun 29, 2021·5 cites·20 claims
- 3390US10669277B2Inhibitors of activin receptor-like kinaseBLUEPRINT MEDICINES CORP·Filed 2019·Granted Jun 2, 2020·9 cites·17 claims
- 3489US11932648B2CDK2 inhibitorsBLUEPRINT MEDICINES CORP·Filed 2022·Granted Mar 19, 2024·1 cites·18 claims
- 3589US11872192B2RET inhibitor for use in treating cancer having a RET alterationBLUEPRINT MEDICINES CORP·Filed 2021·Granted Jan 16, 2024·2 cites·19 claims
- 3687US2024317757A1Compositions useful for treating disorders related to kitBLUEPRINT MEDICINES CORP·Filed 2023·Application pending·0 cites
- 3784US12060354B2Crystalline forms of (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of makingBLUEPRINT MEDICINES CORP·Filed 2021·Granted Aug 13, 2024·1 cites·14 claims
- 3883US11634422B2Inhibitors of activin receptor-like kinaseBLUEPRINT MEDICINES CORP·Filed 2020·Granted Apr 25, 2023·1 cites·30 claims
- 3983US10875837B2Inhibitors of the fibroblast growth factor receptorBLUEPRINT MEDICINES CORP·Filed 2019·Granted Dec 29, 2020·1 cites·6 claims
- 4081US12545684B2CDK2 inhibitorsBLUEPRINT MEDICINES CORP·Filed 2024·Granted Feb 10, 2026·0 cites·20 claims
- 4181US12252494B2Dosing regimens of (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine for treatment of indolent systemic mastocytosisBLUEPRINT MEDICINES CORP·Filed 2022·Granted Mar 18, 2025·1 cites·7 claims
- 4280US2025289801A1Egfr inhibitorsBLUEPRINT MEDICINES CORP·Filed 2024·Application pending·0 cites
- 4379US12595265B2Inhibitors of activin receptor-like kinaseBLUEPRINT MEDICINES CORP·Filed 2023·Granted Apr 7, 2026·0 cites·31 claims
- 4479US10407509B2NTRK2 fusionsBLUEPRINT MEDICINES CORP·Filed 2014·Granted Sep 10, 2019·3 cites·8 claims
- 4578US11964980B2Crystalline forms of (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1- f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of makingBLUEPRINT MEDICINES CORP·Filed 2022·Granted Apr 23, 2024·0 cites·7 claims
- 4678US2026049080A1Wild type kit inhibitorsBLUEPRINT MEDICINES CORP·Filed 2025·Application pending·0 cites
- 4777US12448379B2Wild type kit inhibitorsBLUEPRINT MEDICINES CORP·Filed 2024·Granted Oct 21, 2025·0 cites·33 claims
- 4877US2022315560A1Inhibitors of retBLUEPRINT MEDICINES CORP·Filed 2022·Application pending·0 cites
- 4974US2022213553A1Prkc fusionsBLUEPRINT MEDICINES CORP·Filed 2022·Application pending·0 cites
- 5074US2021284645A1Compositions useful for treating disorders related to kitBLUEPRINT MEDICINES CORP·Filed 2020·Application pending·0 cites
Showing the top 50 of 106 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when BLUEPRINT MEDICINES CORP files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →